Study finds HRT increases the risk of ovarian cancer

16 February 2015

Research by the University of Oxford, published in the prestigious British medical magazine The Lancet, found an extra case for every 1,000 women taking hormone replacement therapy (HRT) drugs for five years from the age of 50, analysis of 52 separate studies.

It found that the risk rises by 40% after five years’ use – the recommended maximum – compared to a woman who has never had the treatment.And while the risk decreases after stopping HRT, 10 years on it is still slightly raised

Lead researcher Sir Richard Peto said that claims there was no risk for short courses of HRT "simply isn't true," adding that the new findings "should edge towards less use rather than more use."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK